Pharvaris (PHVS) Free Cash Flow (2020 - 2026)
Pharvaris' (PHVS) quarterly Free Cash Flow came in at -$57.0 million in Q1 2026, down 41.52% YoY from -$97.5 million in Q1 2025, and down 29.1% on a QoQ basis from -$44.2 million in Q4 2025.
Analysis
Pharvaris (PHVS) Free Cash Flow (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Free Cash Flow data on file, last reported at -$57.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 41.52% year-over-year to -$57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$171.0 million (down 19.21% YoY) and the FY2025 annual result came in at -$154.7 million, down 19.5% from the prior year.
- Free Cash Flow fell to -$57.0 million in Q1 2026, from -$44.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $49676.0 billion in Q3 2023 to a low of -$49691.2 billion in Q2 2023.
- A 5-year average of -$926.4 million and a median of -$29.8 million in 2024 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 325629580.06% in 2023, down 340811256.1% in 2023.
- Tracing PHVS's Free Cash Flow over 5 years: stood at -$20.8 million in 2022, then dropped by 23.0% to -$25.6 million in 2023, then sank by 45.31% to -$37.2 million in 2024, then retreated by 18.82% to -$44.2 million in 2025, then decreased by 29.1% to -$57.0 million in 2026.
- The last three Free Cash Flow figures came in at -$57.0 million (Q1 2026), -$44.2 million (Q4 2025), and -$35.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | -43.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.91 Mn |
| Mar 31, 2026 | -57.03 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Sep 30, 2025 | -35.83 Mn |
| Jun 30, 2025 | -33.96 Mn |
| Mar 31, 2025 | -40.30 Mn |
| Dec 31, 2024 | -37.18 Mn |
| Sep 30, 2024 | 56,936.14 Bn |
| Jun 30, 2024 | -55,830.28 Bn |
| Mar 31, 2024 | -26.29 Mn |
| Dec 31, 2023 | -25.59 Mn |
| Sep 30, 2023 | 49,675.96 Bn |
| Jun 30, 2023 | -49,691.24 Bn |
| Mar 31, 2023 | -27.03 Mn |
| Dec 31, 2022 | -20.80 Mn |
| Sep 30, 2022 | 31,779.58 Bn |
| Jun 30, 2022 | -33,632.36 Bn |
| Mar 31, 2022 | -20.04 Mn |
| Dec 31, 2021 | -14.22 Mn |
| Sep 30, 2021 | -11.80 Mn |